Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102, Bevacizumab, and Camrelizumab in Metastatic Gastric Cancer
NCT06711471Phase 2Recruiting
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trifluridine + tipiracil, bevacizumab and camrelizumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma. Primary endpoint: Progression-Free Survival at 2 years. Started Nov 2024; status: recruiting.
02
Drugs
trifluridine + tipiracilbevacizumabcamrelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06711471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06711471.